NASDAQ:INMB - Nasdaq - US45782T1051 - Common Stock - Currency: USD
2.855
+0.29 (+11.52%)
The current stock price of INMB is 2.855 USD. In the past month the price increased by 24.35%. In the past year, price decreased by -61.14%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.62 | 348.32B | ||
AMGN | AMGEN INC | 14.54 | 162.36B | ||
GILD | GILEAD SCIENCES INC | 14.79 | 142.44B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 121.28B | ||
REGN | REGENERON PHARMACEUTICALS | 12.52 | 61.71B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 54.71B | ||
ARGX | ARGENX SE - ADR | 74.47 | 42.25B | ||
ONC | BEONE MEDICINES LTD-ADR | 7.82 | 32.93B | ||
BNTX | BIONTECH SE-ADR | N/A | 26.45B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 21.78B | ||
INSM | INSMED INC | N/A | 21.10B | ||
BIIB | BIOGEN INC | 8.26 | 19.37B |
INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. The company is headquartered in Boca Raton, Florida and currently employs 22 full-time employees. The company went IPO on 2019-02-04. The firm has three product platforms. The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The Natural Killer Cell Priming Platform includes INKmune, developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that has completed a trial in recessive dystrophic epidermolysis bullosa.
INMUNE BIO INC
225 Ne Mizner Blvd, Suite 640
Boca Raton FLORIDA 92037 US
CEO: Raymond J. Tesi
Employees: 22
Phone: 18589643720
The current stock price of INMB is 2.855 USD. The price increased by 11.52% in the last trading session.
The exchange symbol of INMUNE BIO INC is INMB and it is listed on the Nasdaq exchange.
INMB stock is listed on the Nasdaq exchange.
11 analysts have analysed INMB and the average price target is 11.66 USD. This implies a price increase of 308.48% is expected in the next year compared to the current price of 2.855. Check the INMUNE BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
INMUNE BIO INC (INMB) has a market capitalization of 75.91M USD. This makes INMB a Micro Cap stock.
INMUNE BIO INC (INMB) currently has 22 employees.
INMUNE BIO INC (INMB) has a support level at 2.55 and a resistance level at 3.17. Check the full technical report for a detailed analysis of INMB support and resistance levels.
The Revenue of INMUNE BIO INC (INMB) is expected to grow by 308.19% in the next year. Check the estimates tab for more information on the INMB EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
INMB does not pay a dividend.
INMUNE BIO INC (INMB) will report earnings on 2025-08-07.
INMUNE BIO INC (INMB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.93).
The outstanding short interest for INMUNE BIO INC (INMB) is 27.62% of its float. Check the ownership tab for more information on the INMB short interest.
ChartMill assigns a technical rating of 1 / 10 to INMB. When comparing the yearly performance of all stocks, INMB is a bad performer in the overall market: 98.43% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to INMB. While INMB seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months INMB reported a non-GAAP Earnings per Share(EPS) of -1.93. The EPS decreased by -0.52% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -107.92% | ||
ROE | -137.49% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 78% to INMB. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 24.83% and a revenue growth 308.19% for INMB